Company Description
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye.
The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.
The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally.
STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
| Country | United States |
| Founded | 1982 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 1,115 |
| CEO | Thomas G. Frinzi |
Contact Details
Address: 1911 Walker Ave Monrovia, California 91016 United States | |
| Phone | (626) 303-7902 |
| Website | staar.com |
Stock Details
| Ticker Symbol | STAA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000718937 |
| CUSIP Number | 852312305 |
| ISIN Number | US8523123052 |
| Employer ID | 95-3797439 |
| SIC Code | 3851 |
Key Executives
| Name | Position |
|---|---|
| Thomas G. Frinzi | President, Chief Executive Officer and Chairman |
| Patrick F. Williams | Chief Financial Officer |
| Dr. Keith Holliday Ph.D. | Chief Technology Officer |
| James Francese | Senior Vice President of Commercial Operations - North America and APAC |
| Dr. Scott D. Barnes M.D. | Chief Medical Officer |
| Warren Foust | Chief Operating Officer |
| Brian Moore | Vice President of Investor Relations and Corporate Development |
| Samuel J. Gesten | Chief Legal Officer and Corporate Secretary |
| Dr. Magda Michna Ph.D. | Chief Clinical, Regulatory and Medical Affairs Officer |
| Robert Studholme | Senior Vice President of Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 21, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 21, 2024 | 8-K | Current Report |
| Jun 12, 2024 | 8-K | Current Report |
| May 7, 2024 | 10-Q | Quarterly Report |
| May 7, 2024 | 8-K | Current Report |
| Apr 24, 2024 | ARS | Filing |
| Apr 24, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 24, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 4, 2024 | 8-K | Current Report |
| Mar 18, 2024 | 8-K | Current Report |